Two Approaches, Two Different Goals
Suppression and sequencing are not simply two techniques for managing HS — they reflect two different understandings of what HS is and what treatment needs to accomplish. Suppression treats HS as a condition that needs to be controlled: the goal is to reduce symptoms to a tolerable level through ongoing intervention. Sequencing treats HS as a process that needs to be interrupted: the goal is to correct the internal conditions generating the disease so that it no longer requires continuous management to stay contained.
These are not competing ideologies. In clinical practice, they inform each other. Suppressive interventions serve a real function in acute situations and during the transition period when internal correction is being initiated. The problem arises when suppression becomes the entirety of the treatment approach — when it is the long-term strategy rather than a bridge to something more complete. At that point, the disease continues progressing internally while its surface expression is modulated, and patients experience the trajectory described in this article: initial control, escalating requirements, worsening disease, diminishing returns.
"The goal is not just to control symptoms, but to understand why the condition is occurring in the first place."
What Suppression Accomplishes — and Where It Ends
Suppressive interventions in HS — antibiotics, steroids, biologics, hormonal suppressants — work by interrupting specific signals in the disease process. Antibiotics reduce bacterial burden in lesions. Steroids dampen the acute inflammatory response. Biologics block specific inflammatory molecules. Hormonal suppressants reduce androgen activity.
Each of these interventions addresses a real component of HS. The limitation of each is that it addresses a signal or a consequence while leaving the underlying conditions generating those signals intact. When a biologic blocks TNF-alpha and lesion frequency decreases, the gut dysfunction and hormonal imbalance that are sustaining the systemic inflammatory environment continue operating. When the biologic is discontinued — whether by choice, medical recommendation, or cost — the environmental conditions are the same as they were before treatment began. Often worse, because the disease has progressed during the treatment period.
This is not an argument against all suppressive intervention. It is an argument for understanding what suppressive intervention can and cannot accomplish — and for not treating it as equivalent to correction when it is not.
The Suppression Trap
The suppression trap in HS develops gradually. Initial suppressive treatment produces meaningful benefit — symptoms reduce, quality of life improves, the condition feels manageable. This benefit creates a reasonable expectation that the treatment approach is working. Over time, however, the benefit diminishes: the same intervention requires escalation, the disease develops new manifestations, new sites appear. By the time the trajectory is clearly worsening, the patient has often been on continuous suppressive management for years — and the internal disease has become more structurally established during that time.
The suppression trap is not a consequence of treatment failure. It is a consequence of a treatment approach that was not designed to address the internal process driving the disease. The suppressive interventions did what they were designed to do; the problem is that what they were designed to do is not sufficient to interrupt the disease trajectory.
What Sequencing Means — The Logic of Ordered Correction
Sequenced treatment is built on the recognition that HS is driven by multiple interacting internal systems — and that correcting them requires a specific order that reflects both the biological relationships between those systems and the clinical reality of what the patient's body can process at each stage.
The reason order matters is biological, not procedural. If tissue healing is attempted before the systemic inflammatory load has been reduced, the healing environment is compromised — the same inflammatory conditions that disrupted the tissue continue to impair its restoration. If hormonal correction is attempted before gut function is stabilised, the gut-driven inflammatory input continues to sustain hormonal dysregulation faster than it can be corrected. If recurrence prevention is targeted before the acute disease burden has been meaningfully reduced, the system is being asked to maintain stability that it does not yet have the resources to sustain.
This is why the EPOH Protocol is structured as a five-phase sequence rather than a simultaneous multi-target intervention: each phase creates the conditions that make the subsequent phase possible and effective.
The Ayurvedic principle of Shodhana before Shamana — purification before palliation — reflects the same clinical logic as sequenced treatment. Before the body can receive and respond to treatments directed at restoration and stabilisation, the accumulated inflammatory material (Ama) that is sustaining the disease must first be addressed. Attempting to nourish or restore tissue in the presence of high Ama is, in Ayurvedic terms, like watering a garden in contaminated soil — the input is correct, but the environment cannot use it effectively. Sequencing creates the environment in which each subsequent intervention can actually work.
The Five-Phase Sequence — Why Each Phase Precedes the Next
Phase L — Lowering the Inflammatory Load
The first intervention in sequenced HS treatment is reducing the systemic inflammatory burden — not suppressing specific inflammatory signals, but genuinely reducing the load that is generating them. This involves dietary correction, gut-directed intervention, and lifestyle adjustments that reduce the ongoing inputs sustaining the inflammatory baseline. Until this load is meaningfully reduced, every subsequent intervention is working against an active inflammatory environment that will limit its effectiveness.
This phase is often the most counterintuitive for patients accustomed to suppressive management, because the changes it requires are not the interventions most visibly directed at the skin. The skin improves as a consequence of internal change, not as a direct target of topical or pharmacological intervention at this stage.
Phase I — Internal Healing
With the inflammatory load reduced, the internal systems that were most compromised by it — gut integrity, immune regulatory function, hormonal regulation — can begin genuine restoration. This phase is where personalised formulations directed at specific system correction are introduced. The sequencing matters: introducing system-correction protocols before the inflammatory load has been reduced means those protocols are working in an environment that will rapidly undermine their effects.
Phase F — Functional Detox
As internal healing progresses, the body's own clearance systems — lymphatic, hepatic, renal — require support to process and eliminate the accumulated metabolic material that has been generated by years of chronic inflammation and compromised function. This is not a generalised "detox" in the popular sense — it is targeted support for specific elimination pathways that have been operating under chronic load. Supporting these pathways facilitates the clearance of material that would otherwise continue cycling through the system and sustaining the inflammatory baseline.
Phase E — External Care
Localised external support for affected tissue — directed at facilitating healing of existing lesions, reducing scar tissue formation, and improving the structural integrity of the follicular environment — becomes meaningfully effective only once the internal inflammatory load has been substantially reduced. External care in an uncontrolled internal inflammatory environment produces limited results because the tissue is continuously being disrupted by the internal process. In a reduced-load environment, the same external interventions produce substantially better outcomes.
Phase S — Sustaining
The final phase is directed at building the metabolic and immune stability that prevents the internal conditions from re-establishing after the active correction phases are complete. This is where lifestyle integration — diet, sleep, stress regulation, movement — is codified as ongoing maintenance rather than introduced as an acute intervention. Sustaining is not passive: it is the active maintenance of the internal environment that the preceding phases have created.
Why Sequencing Takes Longer — and Why That Is Not a Limitation
The most common objection to sequenced treatment is that it takes longer than suppressive management to produce visible results. This is true in one sense and misleading in another. Suppressive management produces faster visible results because it targets the visible endpoint of the disease process — the skin manifestation — rather than the process generating it. A steroid injection reduces an abscess in 48 hours; a sequenced gut and hormonal correction reduces the next abscess from forming, but this takes months.
The meaningful comparison is not between short-term symptom reduction and long-term internal correction — it is between where each approach leaves the patient after two years, five years, ten years. Suppressive management, in the absence of internal correction, typically leaves the patient with a more structurally established, more systemically active disease than they had when treatment began. Sequenced internal correction, properly executed, leaves the patient with a less active internal environment, a longer interval between episodes, and in many cases a stable remission that does not require ongoing management to maintain.
This is not a guarantee — individual outcomes vary, and the complexity of advanced disease means that complete remission is not always achievable. But the trajectory of sequenced correction is fundamentally different from the trajectory of suppression alone, and the difference becomes more pronounced over time.
"Unless the underlying causes are addressed, the condition may continue to recur despite treatment."
What Sequencing Requires From the Patient
Sequenced treatment requires a different engagement from patients than suppressive management. It requires patience with a process that produces internal changes before visible ones. It requires trust in a logical framework rather than immediate symptom relief as the primary measure of whether something is working. It requires active participation in dietary, lifestyle, and monitoring components of the treatment protocol.
These are not trivial requirements, and dismissing them as simple is unhelpful. Patients who have been managing HS for years through a suppression model are accustomed to measuring treatment by short-term lesion activity — and a framework that asks them to wait months for visible skin changes while trusting internal improvements they cannot directly observe requires a significant shift in how they understand their treatment.
What makes this shift possible — in clinical experience — is a clear explanation of what is happening and why at each stage of the sequence. When patients understand that the absence of dramatic early skin improvement is not evidence that nothing is changing, but rather that the change being made is internal and precedes visible surface improvement, they are far better positioned to maintain the engagement that sequenced correction requires.